Study wrapper · #511
Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.
Editor's note
This is the strongest design tier in the batch: a meta-analysis of five randomized controlled trials of tesamorelin versus placebo in adults with HIV-associated lipodystrophy, with risk of bias assessed by RoB 2.0 and certainty graded by GRADE. Researchers reported that tesamorelin was associated with statistically significant reductions in visceral adipose tissue (about -28 cm2), trunk fat, limb fat, hepatic fat percentage, and waist circumference, plus an increase in lean body mass, with no significant change in subcutaneous fat, BMI, or CD4 counts. Reported adverse events included arthralgia, myalgia, paresthesia, and injection-site reactions. The pooled effects align tightly with tesamorelin's FDA-approved indication and give this finding real weight, though the evidence base is confined to the HIV lipodystrophy population and rests on only five trials. This is well-supported evidence within that specific setting.
Plain-language abstract
Researchers combined the results of five randomized trials that compared tesamorelin — a lab-made growth-hormone-releasing hormone — against placebo in adults with HIV who had abnormal fat distribution (lipodystrophy). Pooling the data, tesamorelin was associated with meaningful reductions in deep belly fat, trunk fat, limb fat, liver fat, and waist size, and with a gain in lean (muscle) mass. It did not significantly change fat just under the skin, overall body-mass index, or immune (CD4) cell counts, and it did not worsen blood sugar. Reported side effects included joint pain, muscle pain, tingling sensations, and reactions at the injection site, with no serious safety problems flagged. Because this pools several well-designed trials and formally rated the evidence quality, it is among the more reliable summaries available — but it applies specifically to people with HIV-associated lipodystrophy.